Last checked at 
Avacta Group PLC - Wetherby, England-based cancer immunotherapies developer - Hires Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. McLaughlin is a medical oncology drug developer and most recently vice president of New Opportunities at Algeta ASA, a biotech firm which worked on castration resistant prostate cancer treatment.
"Fiona is a seasoned drug developer with an outstanding track record in developing oncology drug candidates and taking them into clinical development," says Chief Executive Alastair Smith.
Current stock price: 135.74 pence
Year-to-date change: up 19%
By Josie O'Brien; josieobrien@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
